Cargando…

Use of national guidelines for the introduction of Drotrecogin alfa (activated)

Detalles Bibliográficos
Autores principales:	Mackenzie, S, Patterson, L, Plenderleith, L, MacKirdy, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099708/ http://dx.doi.org/10.1186/cc2588

Ejemplares similares

Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
por: Vedantham, R, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

A large, single-centre UK registry of drotrecogin alfa-activated use
por: Macchiavello, L, et al.
Publicado: (2007)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
por: Schuerholz, T, et al.
Publicado: (2004)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
por: Rowan, K, et al.
Publicado: (2007)

Drotrecogin alfa (activated): a single-centre experience of 110 patients
por: Fletcher, S, et al.
Publicado: (2010)

Drotrecogin alfa: start early, ensure response, stop early!
por: Jog, S, et al.
Publicado: (2008)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
por: Shulman, R, et al.
Publicado: (2005)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
por: Yan, S, et al.
Publicado: (2008)

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
por: Mirea, L, et al.
Publicado: (2011)

Drotrecogin alfa in sepsis: analysis of outcomes in a UK district general intensive care unit
por: Pathak, H, et al.
Publicado: (2004)

Outcomes and incidence of bleeding events associated with drotrecogin alfa: a single-centre experience of 440 patients
por: Boyle, A, et al.
Publicado: (2010)

Drotrecogin alfa in patients with severe sepsis: experience from a tertiary care center in North India
por: Chawla, R, et al.
Publicado: (2007)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Feasibility of surveillance of ICU-associated infections in Scotland
por: Booth, M, et al.
Publicado: (2006)

Three years experience with drotrecogin alfa (activated) protein C in severe sepsis and septic shock at Salmaniya Medical Complex, Bahrain
por: Mohamed, H, et al.
Publicado: (2007)

Canadian ENHANCE data support the efficacy and safety of drotrecogin alfa (activated) despite higher disease severity than the global ENHANCE population
por: Hall, R, et al.
Publicado: (2005)

Effect of socioeconomic deprivation on intensive care mortality
por: Booth, M, et al.
Publicado: (2003)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Surveillance of ICU-associated infections
por: MacKirdy, F, et al.
Publicado: (2006)

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

Drotrecogin alfa (activated): real-life use and outcomes for the UK
por: Rowan, Kathryn M, et al.
Publicado: (2008)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

Drotrecogin alfa (activated): down and not out, but not really in either
por: Friedrich, Jan O, et al.
Publicado: (2006)

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE
por: Vincent, J, et al.
Publicado: (2004)

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Beale, R, et al.
Publicado: (2004)

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with an APACHE II score of 25 or greater at baseline: results from ENHANCE
por: Doig, C, et al.
Publicado: (2004)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Drotrecogin alfa (activated) reduces the plasma levels of N-terminal prohormone atrial natriuretic peptide and N-terminal prohormone brain natriuretic peptide as markers of cardiac depression in septic patients
por: Hoffmann, U, et al.
Publicado: (2004)

Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

The Use of Drotrecogin Alfa (activated) in a Patient With Severe Acute Respiratory Syndrom
por: Farooq, Warda, et al.
Publicado: (2003)

The epidemiology of sepsis in Scottish intensive care units
por: MacKirdy, F, et al.
Publicado: (2003)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_rmn4f5kkt3857gr5u0tuc9ifd1